Liver Disease Treatment Market Report 2031 by Segments, Geography, Dynamics, Recent Developments, and Strategic Insights

The liver disease treatment market size is projected to reach US$ 6.94 billion by 2031 from US$ 4.41 billion in 2023. The market is expected to register a CAGR of 5.8% during 2023–2031. Increasing use of hybrid systems for imaging owing to the benefits offered as compared to the conventional systems are likely to remain key trends in the market.

Liver Disease Treatment Market Analysis

Liver disease treatment market is driven by the increasing prevalence of liver diseases along with surge in technological advancement for the treatment and diagnosis of such conditions. There have been various factors contributing to the increasing prevalence of liver disease, increased consumption of alcohol, surging liver infections such as hepatitis A and B, and increasing incidence of liver cancer, and others. Additionally, surging collaborations and partnerships among market players for the development of new treatment and diagnostic techniques are expected to further contribute to the overall market growth.

Liver Disease Treatment Market Overview

Liver disease treatment market is expected to grow moderately during the forecast period owing to the rising prevalence of liver diseases and technological advancements in imaging techniques. Additionally, surging collaboration and partnership among market players is likely to create ample opportunities however, the high cost of imaging techniques and stringent regulatory policies are expected to hamper the market growth. Furthermore, North America accounts for the major share followed by Europe, and Asia Pacific is expected to show significant growth over the next few years. North America consists of high developed countries with developed healthcare infrastructure along with high disposable income. Asia Pacific consists of developing countries with and increasing number of liver disease cases, government initiatives taken for liver treatment, and a rise in the development by the market players for the treatment of liver diseases. The change in the culture, lifestyle and consumption of alcohol is expected to increase the number of liver diseases number and eventually the market for liver treatment is anticipated to grow significantly.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Liver Disease Treatment Market: Strategic Insights

Liver Disease Treatment Market

• 
  CAGR (2023 - 2031)

  5.8%
• Market Size 2023
  US$ 4.41 Billion
• Market Size 2031
  US$ 6.94 Billion

Market Dynamics

GROWTH DRIVERS

• Increasing Prevelance of liver diseases creates demnad for liver imaging

FUTURE TRENDS

• Increasing collaborations and partnerships among market players leads to new product launches

OPPORTUNITIES

• Increasing use of hybrid systems for imaging owing to the benefits offered as compared to the conventional systems

Key Players

• General Electric
• Koninklijke Philips N V
• Siemens AG
• Canon Medical Systems Corporation
• Hitachi Ltd Elekta AB pub
• Neusoft Corporation
• Samsung Healthcare
• BPL Medical Technologies
• Cura Healthcare

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Diseases

• Cirrhosis
• Hepatitis
• Cancer and Other Diseases

Imaging Modality

• Magnetic Resonance Imaging
• Computed Tomography
• Ultrasound
• Other Modalities

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Liver Disease Treatment Market Drivers and Opportunities

Increasing Prevalence of Liver Diseases to Favor Market Growth

There has been a significant rise in the number of liver diseases across the globe during the previous years. Various factors such as changing lifestyle patterns, diabetes, obesity, metabolic syndrome, and cardiovascular disorders have been leading to an increase in the cases of liver disease. According to National institute of Health, 2023 report, Liver disease accounts for 2 million deaths annually which is 4% of all deaths globally.  Among various liver diseases, the cases of Alcoholic liver disease (ALD) is among the main causes of chronic liver disease worldwide. ALC accounts for 48% of cirrhosis associated deaths in the United States. Liver disease is considered to be the fifth reason cause of death in England & Wales, after heart, cancer, stroke and respiratory disease. Alcohol consumption is said to be a major factor leading to liver diseases among the population in the United States as well as UK. In the UK, alcohol consumption per person across the population has more than doubled in the last half-century. The rise in the number of liver diseases is expected to grow at a significant rate during the forecast period, hence fueling the growth of the market in the coming years.

Partnerships and Collaborations Between Market Players create ample Opportunities for the Market

In recent years, there have been various partnerships as well as collaborations among the players operating in the market. For instance, in January, 2024, Mindray North America, collaborated with Aegle Medical Solutions, to be the sole distributor of its Hepatus-Series Transient Elastography Diagnostic Ultrasound Systems for liver care. Additionally, in December 2023, Clarivate Plc launched VeriSIM Life Translational Index on Cortellis Drug Discovery Intelligence and this new solution is the next step of an intensifying partnership between Clarivate and VeriSIM Life. The integrated workflow provides customers with a multitude of predictive compound safety and efficacy insights, including bioavailability, hepatic and renal clearance, clinical toxicity, first-in-human dose and more. Partnerships and collaborations are considered to offer growth opportunities to the market players. Such growth strategies made by the companies are likely to offer significant growth opportunities for the market players operating in the liver treatment market during the forecast period.

Liver Disease Treatment Market Report Segmentation Analysis

Key segments that contributed to the derivation of the liver disease treatment market analysis are disease and imaging modality.

• Based on disease, the liver disease treatment market is segmented into cirrhosis, hepatitis, cancer and other diseases. The cancer segment held a largest market share in 2023.
• By imaging modality, the market is segmented into magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and other modalities. The computed tomography segment held the largest share of the market in 2023.

Liver Disease Treatment Market Share Analysis by Geography

The geographic scope of the liver disease treatment market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has dominated the market owing to the increasing incidences of hepatitis A, B and C, rise in the number of the liver cancer and nonalcoholic fatty liver diseases. The developments by the market players for the diagnostic imaging equipment and rise in the market consolidation are likely to lead the growth of the liver disease treatment market in the forecast period. In addition, the growth of the medical tourism is the Mexico is attracting more patients for the treatments at cheaper cost. The region is anticipated to continue to hold largest market for the liver treatment in the coming near future. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.

Liver Disease Treatment Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Liver Disease Treatment Market News and Recent Developments

The liver disease treatment market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the liver disease treatment market are listed below:

• The company launched QP-Liver, which improves the diagnosis of diffuse liver diseases through highly accurate quantification of tissue fat and iron from MRI scans. It has been given a CE and UKCA mark for the European Union and United Kingdom respectively, meaning it is cleared to be used in those markets. (Source: Quibim, Company Website, March 2024)
• PerkinElmer Inc launched Vega imaging system, that combines hands-free, automated technology with high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more. (Source: AXIS IMAGING NEWS, Newsletter, April 2022)
• Royal Philips has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Liver Fat Quantification tools as part of the latest release of its ultrasound systems EPIQ Elite and Affiniti, bringing the cost and accessibility advantages of sonography to the diagnosis of early-stage liver disease.  (Source: Royal Philips, Press Release, November 2021)

Liver Disease Treatment Market Report Coverage and Deliverables

The “Liver Disease Treatment Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Liver Treatment market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Liver Treatment market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• liver disease treatment market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the liver disease treatment market
• Detailed company profiles